Searching…
KCSG-LU08-01-Gefitinib Versus Pemetrexed as Second-Line Treatment in Patients With Nonsmall Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy BACKGROUND: Gefitinib was …
2012年10月31日 · GefitinibVersusPemetrexedasSecond-LineTreatmentinPatientsWithNonsmallCellLungCancerPreviouslyTreatedWithPlatinum …
Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01) †
2014年9月16日 · INTEREST研究和KCSG-LU08-01研究即是最好的佐证。 INTEREST研究是一项比较吉非替尼 (易瑞沙)与多西他赛治疗复治晚期NSCLC患者的全球多中心、前瞻性、随机对照Ⅲ期临床研 …
Randomized phase III trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01).
2025年12月29日 · Dive into the research topics of 'Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy …
2014年3月12日 · Sun JM, Lee KH, Kim S, et al. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG …
